Nelson Brad H
Deeley Research Centre, British Columbia Cancer Agency, Victoria, British Columbia, Canada.
J Immunol. 2004 Apr 1;172(7):3983-8. doi: 10.4049/jimmunol.172.7.3983.
IL-2 is a potent T cell growth factor that for many years was assumed to amplify lymphocyte responses in vivo. Accordingly, IL-2 has been used clinically to enhance T cell immunity in patients with AIDS or cancer, and blocking Abs to the IL-2R are used to inhibit T cell responses against transplanted tissues. It was later shown in mice that, unexpectedly, disruption of the IL-2 pathway results in lymphoid hyperplasia and autoimmunity rather than immune deficiency, indicating that the major physiological function of IL-2 is to limit rather than enhance T cell responses. This apparent paradox has recently been resolved with the discovery that IL-2 is critical for the development and peripheral expansion of CD4(+)CD25(+) regulatory T cells, which promote self-tolerance by suppressing T cell responses in vivo. Our new understanding of IL-2 biology prompts a re-evaluation of how best to clinically manipulate this important immunoregulatory pathway.
白细胞介素-2是一种强效的T细胞生长因子,多年来一直被认为可在体内放大淋巴细胞反应。因此,白细胞介素-2已被临床用于增强艾滋病或癌症患者的T细胞免疫力,而针对白细胞介素-2受体的阻断性抗体则用于抑制T细胞对移植组织的反应。后来在小鼠中发现,出乎意料的是,白细胞介素-2信号通路的破坏会导致淋巴样增生和自身免疫,而非免疫缺陷,这表明白细胞介素-2的主要生理功能是限制而非增强T细胞反应。最近随着一项发现,这一明显的矛盾得到了解决,即白细胞介素-2对于CD4(+)CD25(+)调节性T细胞的发育和外周扩增至关重要,这些调节性T细胞通过在体内抑制T细胞反应来促进自身耐受。我们对白细胞介素-2生物学的新认识促使人们重新评估如何以最佳方式在临床上操控这一重要的免疫调节通路。